share_log

天坛生物(600161.SH):所属企业静注人免疫球蛋白(pH4)获得新增适应症临床试验批准通知书

Beijing Tiantan Biological Products Corporation (600161.SH): The affiliated company's intravenous human immunoglobulin (pH4) has obtained a new indication clinical trial approval notice.

Gelonghui Finance ·  Sep 12 17:33

Gelonghui, September 12 | Tiantan Biology (600161.SH) announced that Chengdu Rongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Chengdu Rongsheng”), which belongs to the company, has obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed that Chengdu Rongsheng will carry out clinical trials of the marketed product “intravenous human immunoglobulin (pH4)” (10% ,50ml) in accordance with the submitted plan. New indications: chronic inflammatory demyelinating polyradiculoneuropathy.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment